Kidney Function and the Use of Vitamin K Antagonists or Direct Oral Anticoagulants in Atrial Fibrillation
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with a five-fold increase in the risk for ischemic stroke. Therefore, lifelong use of anticoagulants is crucial to reduce the morbidity and mortality burden of AF. The incidence of AF in chronic kidney disease...
Main Author: | Gencheva Dolina |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2023-09-01
|
Series: | Journal of Cardiovascular Emergencies |
Subjects: | |
Online Access: | https://doi.org/10.2478/jce-2023-0011 |
Similar Items
-
Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study
by: Lihong Tang, et al.
Published: (2020-06-01) -
Clinical outcomes in patients with atrial fibrillation and a history of falls using non-vitamin K antagonist oral anticoagulants: A nationwide cohort study
by: Maxim Grymonprez, et al.
Published: (2023-08-01) -
Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
by: Anetta Undas, et al.
Published: (2019-12-01) -
Clinical Profile and One Year Outcome of Atrial Fibrillation- A Prospective Cohort Study
by: Praveen Satheesan, et al.
Published: (2020-09-01) -
How to level the risk of bleeding while taking anticoagulant therapy in patients with atrial fibrillation?
by: Svetlana A. Berns, et al.
Published: (2022-01-01)